Literature DB >> 24900827

Inhibitors of Factor XIa and Plasma Kallikrein May Treat Thromboembolic Disorders and Many Diabetes Complications.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2014        PMID: 24900827      PMCID: PMC4027593          DOI: 10.1021/ml500084u

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  2 in total

Review 1.  Inhibition of factor XIa as a new approach to anticoagulation.

Authors:  William A Schumacher; Joseph M Luettgen; Mimi L Quan; Dietmar A Seiffert
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-02-05       Impact factor: 8.311

Review 2.  Role of plasma kallikrein in diabetes and metabolism.

Authors:  E P Feener; Q Zhou; W Fickweiler
Journal:  Thromb Haemost       Date:  2013-05-16       Impact factor: 5.249

  2 in total
  1 in total

Review 1.  Factor XIa inhibitors: A review of the patent literature.

Authors:  Rami A Al-Horani; Umesh R Desai
Journal:  Expert Opin Ther Pat       Date:  2016       Impact factor: 6.674

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.